Asia Fresh News

Asia Fresh Stories

Archive for June 4th, 2015

Huawei Accelerates ICT Transformation for a  Better Connected World

leave a comment »

-Showcases innovative solutions and initiatives to enable customers to thrive in a digitised world at CommunicAsia 2015

SINGAPORE, June 2, 2015 /PRNewswire/ — At CommunicAsia 2015 held in Singapore, Huawei will showcase innovative ICT initiatives and solutions that enable businesses and consumers to succeed in the new digitised world.
From Left, David Wei (President of Huawei Southern Pacific) and Ministers officiate the opening ceremony of Huawei booth during CommunicAsia 2015 in Singapore.
From Left, David Wei (President of Huawei Southern Pacific) and Ministers officiate the opening ceremony of Huawei booth during CommunicAsia 2015 in Singapore.

The rapid development of the mobile Internet has significantly changed user behaviour creating a new pattern of traffic consumption featuring five fundamental characteristics: Real-time, On-demand, All-online, DIY, and Social; or ROADS in short. To deliver the ROADS user experience, organisations not only need to construct future-oriented infrastructure that ensures efficient operations and agile innovation, but should also focus on the creation of a healthy and open industry ecosystem where all players along the value chain collaborate and contribute.

“With the core value of the ICT industry shifting to content and applications, a superior user experience is becoming critical to enterprise, operator and government success,” said David Wei, President of Huawei Southern Pacific Region. “However, organisations are challenged by the surge of data traffic coming from the Internet of Things, video streaming and the delivery of different types of digital content, requiring them to improve network capability and capacity, evolve their operations, and transform the way they collaborate with partners and interact with end users.”

During CommunicAsia, Huawei will showcase solutions and initiatives that help enterprises, carriers and governments transform their ICT operations to drive agile innovation, faster service delivery and enhanced user experiences. By applying groundbreaking ICT innovation to solve their toughest challenges, organisations can create a better connected, stronger and sustainable world.

Huawei will also unveil a premium smartphone, demonstrating how it seamlessly combines the best elements of style and technology to deliver a revolutionary user experience. In addition, there will be a dedicated section in the Huawei booth at CommunicAsia for the collaborative work Huawei undertakes with a range of strategic partners including SAP and Intel, to deliver ICT advances that significantly improve the well-being of people and societies.

“As a global end-to-end ICT solutions provider deeply rooted in Asia, we keep a keen watch with the mandates and policies from the Singapore government who always stays at the forefront of ICT infrastructure development. Huawei Singapore is honored to be involved in a lot of the Smart Nations initiatives and private sectors projects in the past 14 years. We hope to continue to contribute positively to Singapore’s future development as a strategic adviser and key working partner,” said Zhoubin, CEO, Huawei Singapore.

Key solutions and initiatives at Huawei’s booth at B2 Basement include:

Smart City:
Governments around the world, including Singapore, want smart cities/nations to enable efficient management, reliable operations, convenient services, and eco-friendly economic growth. Huawei believes that innovative ICT is the core driving force for smart cities/nations. Huawei will demonstrate its commitment to laying a solid foundation that offers flexible information sharing, ubiquitous broadband access, a high level of service agility, and enhanced security for smart city development. Alongside smart solutions, Huawei will be showcasing the latest smart phones and wearable products that will digitally enhance lifestyles through IoT. Huawei’s unique IoT platform will create a smarter future by connecting smart homes to CarFi to personal devices. Huawei will also showcase an open ICT platform to build an efficient, win-win industry ecosystem to promote the deployment of intelligent applications.

Digital inCloud:
Huawei will showcase its Digital inCloud that enables operators to introduce global digital services and contents easily via an inTouch partner alliance. In addition to ensuring additional revenue generation, Huawei Digital inCloud shortens service time to market and accelerates digital transformation. Huawei inTouch partner alliance has aggregated over 2,100 partners with over 200,000 high-quality digital services content, helping carriers to build up the digital ecosystem easily. Huawei Digital inCloud has and will integrate the telecom capabilities of over 56 carriers from 27 countries. At present, the daily telco capability use from Huawei partners has reached up to 6 million.

Service-Driven Distributed Cloud Data Centre (SD-DC2):
Embodying innovations in cloud, Big Data and data management, this next generation data centre helps enterprises build service-driven IT infrastructure that features key capabilities such as service awareness, business intelligence and unified management. In addition, SD-DC2 is open and interoperable with products from third-party vendors, enabling customers to better cope with the fast-changing and dynamic IT environment and to accelerate innovation.

Agile Network:
As a highlight of the latest version of Huawei’s Agile Network architecture, Huawei will demonstrate its Agile Internet of Things (IoT) solution. The solution enables enterprises to build an agile IoT infrastructure to capture infinite business possibilities and to realise the digitisation of areas such as production, manufacturing and logistics.

Huawei P8 Smartphone:
As part of its commitment to bring the latest technology to consumers and create extraordinary connected experiences for people everywhere, Huawei is launching the Huawei P8 smartphone, a perfect blend of technology, sleek styling, usability and revolutionary low light camera features. The Huawei P8 is the culmination of the P series’ rich heritage of style and functionality, and is once again redefining the smartphone market with easy-to-use features that amaze and inspire consumers.

About Huawei
Huawei is a leading global information and communications technology (ICT) solutions provider. Our aim is to enrich life and improve efficiency through a better connected world, acting as a responsible corporate citizen, innovative enabler for the information society, and collaborative contributor to the industry. Driven by customer-centric innovation and open partnerships, Huawei has established an end-to-end ICT solutions portfolio that gives customers competitive advantages in telecom and enterprise networks, devices and cloud computing. Huawei’s 170,000 employees worldwide are committed to creating maximum value for telecom operators, enterprises and consumers. Our innovative ICT solutions, products and services are used in more than 170 countries and regions, serving over one-third of the world’s population. Founded in 1987, Huawei is a private company fully owned by its employees.

For more information, please visit Huawei online at or follow us on:

Photo –
Source: Huawei

Written by asiafreshnews

June 4, 2015 at 9:10 pm

Posted in Uncategorized

SIRFLOX Study Presented at ASCO 2015 Annual Meeting

leave a comment »

-Clinical investigators cite significance of 7.9 month improvement in Progression-Free Survival in the liver for patients with unresectable metastatic colorectal cancer (mCRC) treated first line with SIR-Spheres® Y-90 resin microspheres plus chemotherapy

CHICAGO, June 1, 2015 /PRNewswire/ — The benefits of adding liver-directed SIR-Spheres Y-90 resin microspheres to a current systemic chemotherapy for the first-line treatment of unresectable metastatic colorectal cancer (mCRC) reported in the SIRFLOX study, were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The results of the 530-patient SIRFLOX randomized controlled study, which open new possibilities for combining radiation targeted at liver metastases with first-line systemic treatment of mCRC, were presented by Associate Professor Peter Gibbs, co-principal investigator of the SIRFLOX study and Consultant Medical Oncologist, The Royal Melbourne Hospital, Australia.

“We found that while liver tumours began to grow again after a median of 12.6 months in patients with mCRC who received only first-line chemotherapy, those who also received first-line treatment with SIR-Spheres Y-90 resin microspheres had their liver tumours controlled for a median of 20.5 months. The additional 7.9 months of treatment benefit with the combined first-line SIRFLOX regimen was statistically significant, with a p-value of 0.002 and a hazard ratio of 0.69. This translates to a 31 percent reduction in the risk of tumour progression in the liver for patients treated with Y-90 resin microspheres,” Prof. Gibbs said.

“This finding matters a great deal,” he explained, “because the liver is almost invariably the organ where colorectal cancer spreads to first. While half the patients initially diagnosed with colorectal cancer survive thanks to surgical removal of the primary tumour before the disease has spread elsewhere in the body, liver metastases eventually cause the death of the majority of the remaining hundreds of thousands of patients each year whose tumours spread but are inoperable.”

Prof. Gibbs also told the ASCO audience that liver treatment response rates were significantly higher in patients who received Y-90 resin microspheres in combination with first-line chemotherapy, which consisted of a FOLFOX-based regimen, with or without the addition of bevacizumab. “We observed a hepatic response rate of 78.7 percent in this group, compared to 68.8 percent in the chemotherapy-only group. This was statistically significant, with a p-value of 0.042. Moreover, the rate of complete responses in the liver of SIRFLOX patients who received SIR-Spheres Y-90 resin microspheres, though relatively small at 6.0 percent, was more than three times higher than the 1.9 percent complete response rate among the chemotherapy-only patients. The statistical significance of this finding is very strong, with a p-value of 0.02,” Prof. Gibbs stated.

Other SIRFLOX Clinical Investigators Discuss Study Implications

At a press conference following Prof. Gibbs’s SIRFLOX presentation, Prof. Guy van Hazel, co-principal investigator of SIRFLOX and Clinical Professor of Medicine at the University of Western Australia, Perth, said that “SIRFLOX gives us the data to validate the first-line use of selective internal radiation therapy, or SIRT, with SIR-Spheres Y-90 resin microspheres in mCRC. Until now, we have not had a randomized clinical study large enough to provide Level One evidence supporting first-line use of this treatment.”

“This step forward matters to medical oncologists and their patients, because until the development of Y-90 resin microspheres, there was essentially no place for radiation therapy in the treatment of liver tumours. There was never a question that radiation would work in the liver, but the problem of administering the radiation in a way that spared healthy liver tissue from its effects prevented it from being an ‘equal partner’ with surgery and chemotherapy in treating mCRC, as it is in almost all other forms of cancer,” Prof. van Hazel added.

The principal European investigator of SIRFLOX, Prof. Volker Heinemann, Director of the Comprehensive Cancer Center at the University of Munich, Germany, told the press conference audience that, “Medical oncologists, particularly also at the community level, are only now beginning to recognize that treating liver metastases locally as well as systemically is a very important clinical consideration in the effective management of this difficult-to-treat cancer, and may also open up the possibility of potentially curative liver surgery in some previously unresectable cases.”

“The effect of Y-90 resin microspheres on Progression-Free Survival in the liver, as reported in the SIRFLOX study, is quite pronounced,” Prof. Heinemann continued. “Even in the absence of sufficient data to calculate an overall survival benefit or a significant finding for the primary endpoint of Progression-Free Survival at any site, the outcome of SIRFLOX suggests that oncologists who treat mCRC may now wish to consider earlier use of Y-90 resin microspheres than is presently the case, certainly among those patients whose metastatic disease has been diagnosed primarily in the liver.”

“With SIRFLOX, the Level One evidence is there for every medical oncologist to see and to evaluate in their practice,” he said.

The principal U.S. investigator of SIRFLOX, Dr. Navesh K. Sharma, Assistant Professor of Radiation Oncology and Diagnostic/Interventional Radiology at the University of Maryland Medical Center, which was the largest US clinical site for SIRFLOX, said that, “With 530 patients, SIRFLOX is the largest randomized trial ever conducted that combined an interventional radiology procedure with chemotherapy in oncology.”

“Physicians have been performing SIRT procedures with Y-90 resin microspheres, in the US and around the world, for more than 10 years. We have always felt that this procedure was a unique approach to deliver large doses of radiation to liver tumours, targeted in a way that spares healthy liver tissue. It is important to observe that in SIRFLOX, the clinical benefit that was observed came with an acceptable level of adverse events from adding Y-90 resin microspheres to first-line chemotherapy in mCRC. Oncologists, especially radiation oncologists, have traditionally been very cautious of irradiating large liver volumes because of the adverse effects associated with such treatments. SIRFLOX has shown us, in an unbiased manner that not only can we deliver high doses of radiation to the liver safely with this approach, but we can do so using concurrent chemotherapy. Concurrent chemo-radiation has been one of the most effective ways to treat cancer in general, especially those of gastrointestinal origin,” Dr. Sharma said.

In a further indication of the potential clinical relevance of the combined chemo-radiation regimen studied in SIRFLOX, ASCO has selected the SIRFLOX study results as one of just 71 of the several thousand abstracts reviewed for this meeting as a “Best of ASCO” presentation. “Best of ASCO” papers may be discussed in an ongoing cascade of official follow-up presentations that national oncology leaders will deliver over the coming months to medical oncologists in their countries who were unable to attend the ASCO Congress in Chicago.

SIRFLOX is the first of a group of three studies assessing the results of adding SIR-Spheres Y-90 resin microspheres to first-line chemotherapy in the treatment of mCRC. The other studies are FOXFIRE, a UK clinical trial that completed enrolment in November 2014, and FOXFIRE Global, an international study that completed enrolment in January 2015. The results of the three studies, which together enrolled more than 1,100 mCRC patients, will be combined in a pre-planned assessment of the overall survival benefit of adding SIR-Spheres Y-90 resin microspheres to first-line chemotherapy for mCRC. The combined results are expected in 2017.

The co-principal investigators of FOXFIRE are Professor Ricky Sharma, Clinical Senior Lecturer in Oncology at the University of Oxford, UK, and Dr. Harpreet Wasan of Hammersmith Hospital and the Imperial College Trust, London, UK. Professor Sharma was also the discussant of SIRFLOX at the ASCO Annual Meeting in Chicago. Professor Peter Gibbs is the principal investigator of FOXFIRE Global.

About SIR-Spheres Y-90 Resin Microspheres

SIR-Spheres Y-90 resin microspheres are a medical device used in an interventional radiology procedure known as selective internal radiation (SIRT), or radioembolisation, which targets high doses of radiation directly to liver tumours. The treatment consists of tens of millions of radioactive Y-90 coated resin particles, each no bigger in diameter than a human hair. Interventional radiologists inject these resin particles, or microspheres, into the hepatic artery via a catheter inserted into the femoral artery through an incision in the groin. The Y-90 resin microspheres become lodged in the capillaries that surround liver tumours, where they deliver a high dose of short-range (mean 2.5 mm; maximum 11 mm) beta radiation to the liver tumours, while sparing health liver tissue. The low specific gravity of Y-90 resin microspheres allows the blood flow to evenly distribute the radioactivity within and around the liver tumours.

Key SIR-Spheres Y-90 resin microspheres regulatory authorisations include a full Pre-Market Approval from the US FDA, European Union (CE Mark) and Australian TGA Conformity Assessment certification.

SIR-Spheres Y-90 resin microspheres also have a Premarket Approval (PMA) by the FDA and are indicated in the United States for the treatment of non-resectable metastatic liver tumors from primary colorectal cancer in combination with intra-hepatic artery chemotherapy using floxuridine. SIR-Spheres Y-90 resin microspheres are approved for the treatment of inoperable liver tumors in Australia, the European Union (CE Mark), Argentina (ANMAT), Brazil, and several countries in Asia, such as India and Singapore.

About Sirtex

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve treatment outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres Y-90 resin microspheres. Approximately 50,000 doses have been supplied to treat patients with liver cancer at more than 800 medical centres in over 40 countries.

For more information, please visit

SIR-Spheres® is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd


Gibbs P et al. 2015 ASCO Annual Meeting; J Clin Oncol 2015; 33 (Suppl): Abs 3502.


Logo –
Logo –
Source: Sirtex Medical Limited

Written by asiafreshnews

June 4, 2015 at 8:48 pm

Posted in Uncategorized

Autostadt’s 15th Anniversary Celebration

leave a comment »

WOLFSBURG, Germany, June 1, 2015 /PRNewswire/ — The Autostadt in Wolfsburg celebrated its 15th anniversary on 30th and 31st May with a unique journey around the world. An exclusive programme featuring more than 300 artists from six continents was presented at different locations throughout the park.


Autostadt CEO Otto F. Wachs thanked the visitors, the almost 1,000 employees, and the heads of management for this accomplishment. He also recalled the theme park’s beginnings: “In the months before the Autostadt opened in 2000 we had no idea how things would develop over the next few years. We believed in our vision, of course, but there was no guarantee of its success. Since then, many attempts have been made to copy the Autostadt – and not only in Germany and Europe. In the meantime, our theme park on the Mittelland Canal has attracted more than 30 million guests, making it the world’s leading automotive destination. The special programme marking the Autostadt’s 15th anniversary is our way of expressing our heartfelt thanks.”

The highlight of the celebration was a dance finale followed by spectacular fireworks. Around 35,000 visitors joined in the celebrations this weekend. Guests could also see the 48 metre-high Car Towers decorated with inscriptions commemorating “15 Years”.

Further information and photo downloads at:

About the Autostadt in Wolfsburg – The world’s leading automotive destination

As a communications platform for the Volkswagen Group, the Autostadt in Wolfsburg focuses on the Volkswagen corporate values and all aspects of mobility in line with the theme: “People, cars and what moves them.” The Autostadt is the world’s largest new car delivery centre and home to the ZeitHaus, the world’s most frequently visited car museum. Featuring a variety of cultural events, including the annual Movimentos Festival, the Autostadt is a well-known international meeting place for culture enthusiasts.

Contacts: Autostadt GmbH – International Media – Phone: +49-(0)5361-40-14-41, Email:
Source: Autostadt GmbH

Written by asiafreshnews

June 4, 2015 at 8:21 pm

Posted in Uncategorized

Laird Antennas Improve Passenger Experience in Major International Airport

leave a comment »

— Fewer antennas provide reliable coverage while minimizing installation all from compact form factor

TAOYUAN CITY, May 29, 2015 /PRNewswire/ — Global technology leader Laird (LRD: London) announces today that its Infrastructure Antenna Solutions were chosen to provide an in-building wireless reception solution for Terminal One of the Taiwan Taoyuan International Airport.

Photo –
Logo –

Laird’s CMD Low PIM Ceiling Mount and PAS Low PIM pole mount panel antennas offer the reliable and robust cellular signals and mobile data which are essential to the success of a modern airport. More and more travelers rely on mobile phones and cellular data while inside airports. Even the businesses serving those travelers are also using wireless data more than ever before.

As one of the 15 busiest airports in the world, Taiwan’s Taoyuan International Airport understands the challenge and appreciates the value of providing reliable wireless reception for businesses and passengers. When the Airport Authority decided to expand the airports capacity to 15 million passengers per year, designers knew increasing cellular and wireless data capacity for those travelers was essential to attract the best businesses and maintain a high quality passenger experience.

Because of their industry leading performance and design, Laird’s multi-port CMD and PAS antennas were chosen to build the wireless network inside the Terminal One passenger terminal that enables high performance 3G / 4G and LTE coverage in all high density public hallways and corridors.

“Multi-port functionality means fewer antennas are needed to provide excellent coverage and throughput because of their ability to transmit and receive cellular and data signals at the same time from a single, low-profile design,” explains Senior Vice President of Infrastructure Antenna Solutions for Laird, Monty Rohde. This improves the ease of installation while the low profile design blends into the architecture of the building to be more visually appealing.

Rohde adds, “We are proud to be selected as a trusted partner to provide an enhanced wireless reception solution used in such a communication critical public venue as Taiwan Taoyuan International Airport. Enabling reliable connectivity in a high traffic, public transportation environment requires the performance engineered reception products and coverage capabilities, which Laird antennas are designed to offer.”

More information about Laird’s Infrastructure Antenna Solutions can be found by visiting

About Laird

Laird is a global technology company focused on providing systems, components and solutions that protect electronics from electromagnetic interference and heat, and that enable connectivity in mission critical systems through wireless applications and antenna systems.

Products are supplied to all sectors of the electronics industry including the Automotive, Mobile Device, Healthcare/ Medical, Computer/ Gaming, Telecommunications, Industrial/ Production, and Transportation markets.

Laird, a unit of Laird PLC, employs over 9,000 employees in more than 50 facilities located in 19 countries.

For the latest news or more information, visit: | | |

© 2015 All rights reserved. Laird, Laird Technologies and the respective logos are trademarks owned by Laird Technologies, Inc. and/or Laird PLC, either directly or indirectly through one or more subsidiaries. Other products, logos, and company names mentioned herein, may be trademarks of their respective owners.
Source: Laird

Written by asiafreshnews

June 4, 2015 at 8:13 pm

Posted in Uncategorized

Compromised experiences are hindering in-air Wi-Fi adoption finds Strategy Analytics

leave a comment »

— JetBlue, American Airlines, Delta and United may need to rethink their strategies

BOSTON/PRNewswire/ — According to the newly published Strategy Analytics report “Computing in the Clouds” while 50% of travelers connected to in-airport Wi-Fi just 8% connected to in-flight Wi-Fi.

Distinct User Devices by Household Income. Source:  AppOptix
Distinct User Devices by Household Income. Source: AppOptix

Logo –

Photo –

Airlines have been seeking to turn in-flight Wi-Fi into a bigger revenue stream. To achieve this they have been engaging in unexpected partnerships. JetBlue recently announced plans to partner with Amazon and Southwest with Beats. These partnerships will be ever more important to monetize travelers earning less than $50K as that segment significantly under-indexes in usage while in the air. In fact, this demographic segment represents half the number of sessions on planes that it represents elsewhere. The data indicate that this user segment is impacted by cost – which these partnerships – could help overcome.

Curiously, the group with the most usage is actually those earning between $50K and $75K. This is likely the result of higher earners relying on devices not under measurement – such as PCs – to be productive while working and the likelihood they are able to treat the cost as a reimbursable business expense. Understanding the stratification of users is useful to developing business models that appeal to each unique segment.

Click here for the report:

According to Joshua Martin, Chief Researcher of the Application Strategy group, “Airlines have a captive audience – and that is hugely valuable – especially to services that are facing entrenched competitors. By creating partnerships airlines offer value to fliers, drive fixed revenue from their Wi-Fi services and allow partners to gain exposure to an audience. It is truly a win-win for all companies involved. We see this as a business model that should be deployed more broadly in airlines and across the travel ecosystem.”

These findings and more will be discussed by Strategy Analytics at the Online Marketing Strategies for Travel Conference in Miami on Wednesday, June 3.

About Strategy Analytics

Strategy Analytics, Inc. provides the competitive edge with advisory services, consulting and actionable market intelligence for emerging technology, mobile and wireless, digital consumer and automotive electronics companies. With offices in North America, Europe and Asia, Strategy Analytics delivers insights for enterprise success.

US Contact: Joshua Martin, +1 617 614 0700,

Photo –

Source: Strategy Analytics

Written by asiafreshnews

June 4, 2015 at 6:27 pm

Posted in Uncategorized

CENX Joins the VMware Technology Alliance Partner Program

leave a comment »

OTTAWA, Ontario/PRNewswire/ — CENX, a global leader of Service Orchestration solutions for software-defined and virtualized networks, today announced it has joined the VMware Technology Alliance Partner (TAP) program. Members of the TAP program collaborate with VMware to deliver innovative solutions for virtualization and cloud computing. The diversity and depth of the TAP ecosystem provides customers with the flexibility to choose a partner with the right expertise to satisfy their unique needs.

“We welcome CENX as a valued member of the VMware TAP program,” said Howard Hall, senior director, Global Technology Partnering Organization, VMware. “This membership means customers can take full advantage of a streamlined virtualization and cloud infrastructure experience. VMware provides an online marketplace, VMware Solution Exchange (VSX), where customers can learn more about CENX’s collaboration with VMware and our continued goal commitment to developing breakthrough technologies that can transform business.”

“Service providers are eager to deploy Network Functions Virtualization (NFV) and are looking for solutions to overcome the operational challenges this new paradigm brings,” said Andrew McDonald, senior vice president of Product Management, CENX. “Joining the VMware TAP program allows CENX to collaborate with industry leaders to deliver proven lifecycle service orchestration for NFV.”

With thousands of members worldwide, the VMware TAP program includes best-of-breed technology partners with the shared commitment to bring the best expertise and business solutions for each unique customer environment.

About CENX
CENX provides Service Orchestration solutions that automate the entire lifecycle of advanced data services in software-defined networks , bridging physical and virtualized network functions. We harness the power of big data, distributed virtualized computing and real-time analytics to dynamically orchestrate and assure services across multiple network technologies and providers. CENX solutions are deployed by service providers worldwide to create new revenue streams, gain service agility, reduce operational costs, and deliver quality-assured data services.

VMware is a registered trademark of VMware, Inc. in the United States and other jurisdictions. The use of the word “partner” and/or “partnership” does not imply a legal partnership relationship between VMware and any other company.

Links and search terms

CENX, Cortx Service Orchestrator, Lifecycle Service Orchestration, LSO, Cloud, data center, software-defined data center, SDDC, Ethernet services, IP Services, software-defined networking, SDN, network functions virtualization, NFV, big data analytics

Follow CENX

Contact: Hannah Whitrow, Zonic Group PR,, +44 (0)1672 550126

Source: CENX
Related Links:

Written by asiafreshnews

June 4, 2015 at 6:20 pm

Posted in Uncategorized

ASCO 2015: Superior Overall Survival for Afatinib Compared to Erlotinib Demonstrated in Head-to-head Trial in Patients with Previously Treated Advanced Squamous Cell Carcinoma of the Lung

leave a comment »

— In the Phase III LUX-Lung 8 trial, afatinib* significantly improved overall survival compared to erlotinib, reducing the risk of death by 19% in patients with advanced squamous cell carcinoma of the lung, previously treated with first-line chemotherapy[1]
— Afatinib significantly delayed progression of lung cancer (primary endpoint) and improved control of cancer-related cough and shortness of breath compared to erlotinib[1],[2]
— The overall rate of severe adverse events (≥ grade 3) was similar between both therapies, with differences observed in the incidence of certain side effects[1],[2]
— Global regulatory submissions are planned later this year to treat this patient population

INGELHEIM, Germany, RIDGEFIELD, Conn. and BRACKNELL, United Kingdom /PRNewswire/ — Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib* and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.[1] Significantly more patients treated with afatinib were still alive at one year compared to those treated with erlotinib (36.4% vs. 28.2%).[1] The details of the OS analysis (abstract #8002 Oral presentation, Lung Cancer Non-Small Cell Metastatic,  Sunday May 31, 8:00-11.00, N Hall B1) will be presented today at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA.

The complete results from this study will be the basis for global regulatory submissions later this year. Afatinib is not approved for use in patients with SCC of the lung.

OS was the key secondary endpoint of this randomised Phase III head-to-head trial, and was analysed following positive results for the primary endpoint of progression-free survival (PFS) presented in 2014.[2] The updated analysis of PFS confirmed a significant reduction in the risk of cancer progression by 19% in patients treated with afatinib compared with erlotinib.[1] The delay in cancer progression seen with afatinib treatment was accompanied by improved control of cancer-related symptoms: a higher proportion of patients treated with afatinib reported improvement in cough (43.4 vs. 35.2%), shortness of breath (51.3 vs. 44.1%) and overall well-being/quality of life (35.7 vs. 28.3%) compared with erlotinib.[1 ]

LUX-Lung 8 clinical trial investigator Professor Jean Charles Soria, Head Drug Development Department, Gustave Roussy Cancer Centre, Paris, France commented: “Squamous cell lung cancer is a difficult-to-treat disease with extensive comorbidities, and patients would benefit from more treatment options. The results of LUX-Lung 8 are very encouraging because they illustrate the clinical relevance of targeting ErbB receptors in this disease. International guidelines recognise erlotinib as a second-line treatment option for squamous cell carcinoma of the lung, and improved outcomes demonstrated with afatinib suggest this treatment could offer additional benefits for this patient population.”

The rate of severe adverse events was similar between afatinib and erlotinib treatment arms (57.1 vs. 57.5%).[1] A higher incidence of severe diarrhoea and stomatitis (mouth sores) was observed with afatinib compared to erlotinib (grade 3/4 diarrhoea: 9.9/0.5 vs. 2.3/0.3%, grade 3 stomatitis: 4.1 vs. 0.0%), while a higher incidence of severe rash/acne was reported with erlotinib compared to afatinib (grade 3 rash/acne: 10.4 vs. 5.9%).[1] See abstract #8002 for full details.

Mehdi Shahidi, Medical Head, Solid Tumour Oncology, Boehringer Ingelheim commented: “Following the approval of afatinib in more than 50 countries for the treatment of specific types of  EGFR mutation-positive lung cancer and positive overall survival data in patients with the most common EGFR mutation, we are proud to present another piece of evidence for afatinib showing it can prolong survival of patients with squamous cell lung cancer. At Boehringer Ingelheim we are committed to research and development in areas of high unmet need such as this. It is our goal that afatinib can become a new treatment option for these cancer patients in the near future.”

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer comprising over 85% of lung cancer cases.[3],[4] SCC, a type of lung cancer which develops in the cells lining the airways, represents approximately 30% of NSCLC cases.[5],[6] Treatment options are limited and SCC of the lung is associated with a poor prognosis, with less than 5% of patients with advanced SCC surviving for five years or longer. [7],[8]

LUX-Lung 8 was conducted across 23 countries and is the first prospective trial to compare two different tyrosine kinase inhibitors (TKIs) in patients with advanced SCC of the lung (n=795).

Afatinib is approved in more than 50 countries for the first-line treatment of distinct types of EGFR mutation-positive NSCLC (under the brand names: GIOTRIF® / GILOTRIF®). Approval of afatinib in this indication was based on the primary endpoint of PFS from the LUX-Lung 3 clinical trial where afatinib significantly delayed tumour growth when compared to standard chemotherapy. [9] In addition, afatinib is the first treatment to show an OS benefit for patients with specific types of EGFR mutation-positive NSCLC compared to chemotherapy.[10] A significant OS benefit was demonstrated independently in the LUX-Lung 3 and 6 trials for patients with the most common EGFR mutation (exon 19 deletions; del19) compared to chemotherapy. [10]

*Afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF® and in the U.S. under the brand name GILOTRIF® for use in patients with distinct types of EGFR mutation-positive NSCLC. Registration conditions differ internationally, please refer to locally approved prescribing information. Afatinib is under regulatory review by health authorities in other countries worldwide. Afatinib is not approved in other indications.

Notes to Editors

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

About afatinib*:

*Afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF® and in the US under the brand name GILOTRIF® for use in patients with distinct types of EGFR mutation-positive NSCLC. Registration conditions differ internationally, please refer to locally approved prescribing information. Afatinib is under regulatory review by health authorities in other countries worldwide. Afatinib is not approved in other indications.

About Boehringer Ingelheim in Oncology

Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

For more information please visit

Media Contact

Boehringer Ingelheim
Corporate Communications
Media + PR
Susanne Granold
55216 Ingelheim/Germany
Phone: +49-6132-77-93319
Fax: +49-6132-77-6601

Further Media Channels

[1] Soria JC, et al. Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8). Abstract #8002 presenred at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, USA. 29 May – 2 June 2015.

[2] Goss GD, et al., A randomized, open-label, phase III trial of afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: LUX-Lung 8 (LL8). Abstract #1222O presented at the European Society for Medical Oncology (ESMO) 2014 Congress, Madrid, Spain. 26 – 30 September 2014.

[3] Tessen HW, et al. The treatment of lung cancer in German outpatient centres. Data from a clinical registry – TLK Registry. Onkologie. 2011;34 (Suppl.6)(Poster P533):153.

[4] Howlader, N. et al. SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD,, based on November 2012 SEER data submission, posted to the SEER web site, 2013.

[5] Atlas of Genetics and Cytogenetics in Oncology and Haematoogy. Lung: Non-small cell carcinoma. Available at Accessed April 2015.

[6] Bryant A and Cerfolio RJ. Differences in Epidemiology, Histology, and Survival Between Cigarette Smokers and Never-Smokers Who Develop Non-small Cell Lung Cancer. Chest 2007;132:185–192.

[7] Cancer Monthly. Lung Cancer (NSCLC). Available at: Accessed April 2015.

[8] Cetin et al. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. Clin Epidemiol. 2011;3:139–148.

[9] Sequist L, Yang J, Yamamoto N, et al. Phase III Study of afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutations. J Clin Oncol 2013;DOI: 10.1200/JCO.2012.44.2806.

[10] Wu Y-L, Zhou C, Hu C-P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. J Clin Oncol 2014;DOI:10.1016/S1470-2045(13)70604.

Source: Boehringer Ingelheim

Written by asiafreshnews

June 4, 2015 at 6:15 pm

Posted in Uncategorized

Computex 2015: Microsoft showcases new Windows 10 devices from partners and broadens the ecosystem opportunity

leave a comment »

— Nick Parker, Microsoft corporate vice president, demonstrates the latest Windows hardware innovations and details new IoT agreement with Toshiba.

TAIPEI /PRNewswire/ — Wednesday during a keynote address at the Taipei International Convention Center, Nick Parker, corporate vice president OEM Division, Microsoft Corp., discussed how Windows 10 is enabling the next generation of devices and cloud-based solutions. Parker highlighted the vast opportunities that Windows 10 creates for partners to grow their businesses by selling the innovative Windows 8.1 devices that are in the marketplace now, promoting the great experience that Windows 10 will offer on those devices when upgraded, and building new hardware across traditional and emerging device categories. These new devices will bring Windows 10 to life when it becomes available in 190 countries around the world on July 29and in the following months.

Photo –

Photo –

Photo –

Photo –

Photo –

Photo –

Logo –

Parker was joined onstage by Tony Prophet, corporate vice president for Windows and Search Marketing, andRoanne Sones, general manager of Windows Engineering. Prophet highlighted the ambitious goal of 1 billion devices running Windows 10 in the next two to three years and discussed how Microsoft will drive excitement and demand for Windows 10 and new devices. Sones demonstrated rich new experiences and scenarios that Windows 10 enables including Start menu enhancements, universal apps and drivers, multitasking, and PC security features. She demonstrated the latest innovations in Cortana,1 Continuum, Microsoft Edge and Windows Hello,2 and she discussed how DirectX 12 will improve the gaming experience, as well as the opportunity for OEMs to develop unique hardware to light up these new capabilities.

Parker shared Microsoft’s commitment to hardware partners to foster opportunities, drive innovation, increase demand and grow the market for Windows devices. “Our device partners continue to push the envelope of innovation, developing stunning PCs that are sure to delight customers,” said Parker. “And our commitment to broaden the ecosystem opportunity with Windows 10 is revolutionizing how people interact with their devices and create new opportunities for revenue growth.”

Parker highlighted an array of devices, some never before seen, designed for Windows 10 including PCs from Acer, ASUS, Dell, HP and Toshiba:

  • Acer Z3-710 is an all-in-one PC that delivers powerful computing and enhanced audio in a slim, 1.4-inch-thin chassis.
  • ASUS Transformer Book T100HA is a 2-in-1 laptop with a detachable keyboard that boasts up to 14 hours of battery life and a tablet measuring 8.45mm and 580g.
  • ASUS Zen AiO Z240 features the latest quad-core Intel Core i7 CPU, gaming-grade NVIDIA GTX 960M graphics, a 3-D camera and a six-speaker stereo sound system.
  • Dell XPS 15, shown publicly for the first time and optimized for Windows 10, features the same virtually borderless InfinityEdge display that made the XPS 13 an industry leader.
  • A new x2 from HP is a 2-in-1, ultra-portable, “tablet first” detachable — with an innovative magnetic hinge design that makes the device flexible and lappable — and with Windows 10, users can transition seamlessly from tablet to PC mode and back again in an instant.
  • A new HP tablet for mobile productivity has revolutionary note-taking capabilities.
  • A new Toshiba PC enables Windows Hello with the latest in biometric security technology, including a face-authentication camera, an Ultra HD 4K screen and optimization for Cortana.

In addition Parker demonstrated two new PC form factors:

  • FoxConn Kangaroo is an ultra-portable desktop PC that turns your TV into a full Windows PC, including a fingerprint reader to support Windows Hello and up to six hours of battery life.
  • Quanta Compute Plug is a mini-PC in a power adapter instead of a stick. Plugged into the HDMI port, it turns a TV into a smart computer and enables users to control their TV using Cortana via Bluetooth remote or headset.

Also showcased was a new GPU from NVIDIA that enables a premium, high-performance gaming experience on Windows 10. GeForce GTX 980 Ti sets a new benchmark in gaming performance, delivering an exciting new level of capabilities with three times the performance and three times the memory than previous generations (versus GTX 680). It gives users the power to play the latest games in stunning 4K resolution and supports key DirectX 12 features such as Volume Tiled Resources and Conservative Rasters to enable striking new graphics effects on Windows 10.

In the emerging category Parker highlighted the Internet of Things (IoT), where connected sensors in equipment and other common devices come together with mobile phones, tablets and the cloud to enable rich new possibilities across a range of industries. Parker announced a new collaboration between Microsoft and Toshibato build next-generation Windows- and Azure-powered IoT solutions. The companies expect to release a complete offering for the transportation and logistics industry, from devices to services, including state-of-the-art hardware such as an onboard video recorder that can also track vehicle data and analyze driver behavior. This also includes a ruggedized environmental device with up to 12 sensors onboard, a military-grade case and a battery capable of six months’ continuous operation that will run on the Azure infrastructure to track shipping and ensure that goods arrive on time, undamaged and in a predictable manner. Parker also showed Crestron Pyng, an elegant home-automation technology powered by Windows embedded services that connects lighting, shades, audio, thermostats, door locks and security systems, and utilizes Azure IoT services so everything works together intelligently to make life easier. Connected devices like these can help both individuals and businesses save time and money.

Microsoft at Computex
Visitors to Computex Taipei this week can view the new Windows 10 devices, along with the ruggedized TZ1000 transportation tracking device from Toshiba, at the Microsoft Booth located in Nangang Exhibition Hall 4F, Area L, booth No. 0110. The show is open through June 6.

Founded in 1975, Microsoft (Nasdaq “MSFT”) is the worldwide leader in software, services, devices and solutions that help people and businesses realize their full potential.

1 Cortana available in select markets at launch; experience may vary by region and device.
2 Windows Hello requires specialized hardware, including fingerprint reader, illuminated IR sensor or other biometric sensors.

Note to editors: For more information, news and perspectives from Microsoft, please visit the Microsoft News Center at Web links, telephone numbers and titles were correct at time of publication, but may have changed. For additional assistance, journalists and analysts may contact Microsoft’s Rapid Response Team or other appropriate contacts listed at

Source: Microsoft Corp.

Related stocks: HongKong:4338 NASDAQ-NMS:MSFT

Written by asiafreshnews

June 4, 2015 at 6:13 pm

Posted in Uncategorized

Personna® Medical Showcases DermaBlade® At The 23rd World Congress of Dermatology

leave a comment »

VERONA, Va. /PRNewswire/ — Personna Medical, a leading provider of high-quality blades for medical applications, announced today that it will showcase the world’s premier shave biopsy tool, the Personna DermaBlade® at the 23rd World Congress of Dermatology (“WCD”) Meeting in Vancouver, British Columbiawhich takes place on June 8-12, 2015. Visit Personna Medical at booth #1937.

Video –
Photo –
Logo –

The DermaBlade was invented by dermatologist, Dr. Robert Segal. It is a flexible, sterile tool that makes the skin biopsy process safer for the patient and much simpler for the user.

This is the first time that Personna Medical has exhibited at the WCD show. The 23rd WCD will be the largest international gathering of dermatologists and professionals dedicated to skin health from all sectors. The WCD takes place once every four years.

Long known for high quality manufacturing and edge quality, Personna Medical will enable WCD attendees to experience the Personna DermaBlade difference first hand at its interactive trial station. The DermaBlade is disposable and very flexible, yet extremely sharp, featuring Microcoat® technology that provides clean excisions and minimizes patient tissue trauma. The DermaBlade can be used for removal of skin proturberances, saucerization, levelization and shave biopsy at any level of the dermis. DermaBlade provides the user with stability, control and precision.

In addition to the DermaBlade, Personna will demonstrate many of its other products, including stainless double edge blades, prep razors and pathology blades made for the needs of today’s dermatologist.

Bob Senesac, Director of Marketing, said, “Personna Medical is excited to be exhibiting at the World Congress of Dermatology in Vancouver. We are looking forward to reaching new customers from across the globe with the DermaBlade product. We hope that as attendees visit our booth and review  the DermaBlade demonstrations, that they learn that the DermaBlade is the premier shave biopsy instrument in the world today. We’re looking forward to finding new customers through these efforts.”

Personna is one of the largest producers of professional, medical and industrial blades with manufacturing facilities in North America. Personna is dedicated to creating blades and bladed products that satisfy the needs of professional, medical and industrial customers. From the most basic to the most advanced product, Personna is dedicated to delivering quality, performance and innovation.

Contact: Bob Senesac
Tel: +1-540-248-1683
Personna: Verona, VA

Source: Personna Medical

Written by asiafreshnews

June 4, 2015 at 5:48 pm

Posted in Uncategorized

Ras Al Khaimah Free Trade Zone Shares Business Set-Up and Expansion Benefits With Investors in China

leave a comment »

RAS AL KHAIMAH, UAE, May 29, 2015 /PRNewswire/ —

His Highness Sheikh Ahmad Bin Saqr Al Qasimi, Chairman, Ras Al Khaimah Free Trade Zone (RAK FTZ), led a free zone delegation to China in order to share the advantages and benefits of setting up and expanding businesses at RAK FTZ with Chinese investors.

(Photo: )

Both HH Sheikh Ahmad Bin Saqr Al Qasimi and Ramy Jallad, Acting CEO of RAK FTZ, conducted high-level meetings and seminars with key government and investment bodies, as well as local companies, and led meetings in the Chinese cities of Guangzhou, Shenzhen, Foshan and Hong Kong. The meetings took place from 24-28 May 2015. It was RAK FTZ’s second road show in China. A free zone delegation visited Beijing in November 2014.

“Since the UAE and China established diplomatic relations more than 30 years ago, bilateral cooperation between the two countries has produced continuous growth across numerous economic sectors in both nations,” HH Sheikh Ahmad said. “Economic development is particularly beneficial to Chinese investors at RAK FTZ, where they can operate free of taxation, with full ownership of their companies and a full range of business set-up and support services to ensure their success.”

RAK FTZ has attracted interest from several Chinese investors who have set up companies in the free zone. They include, among others: Li Jie International Trading FZC, which handles the procurement and processing of spent catalysts and non-ferrous metallic residues from petrochemical businesses; Stimes Fabric and Steel Structure FZE, which trades in building materials, tents, awnings and tarpaulin; and Fu Yu Trading FZE, which trades in garments, gifts, toys and games.

The free zone is also home to Chinese-owned Hinloon Trading FZE, which does business in packaging machinery and spare parts. The company opened at RAK FTZ in 2013 to take advantage of the free zone’s location, which provides easy access to customers in the Middle East and Africa. The company plans to expand from its flexi desk into a RAK FTZ warehouse.

“We set up our operations at RAK FTZ because we were able to get good value for our money, and it was easy to communicate with their staff,” said Anson Chen, the company’s Managing Director. “We were also pleased with the facilities and business set-up services that RAK FTZ provided.”

About Ras Al Khaimah Free Trade Zone:

Ras Al Khaimah Free Trade Zone (RAK FTZ) provides award-winning services and world-class facilities, enabling clients to quickly and efficiently set up and grow profitable companies in the United Arab Emirates. Home to more than 8,000 active companies from over 100 countries and over 50 industry sectors, RAK FTZ offers completely tax-free status to clients, allows for 100 per cent foreign ownership and unrestricted repatriation of profits, in addition to many other business-friendly incentives.

Less than an hour’s drive from Dubai, RAK FTZ offers significant geographical advantages for clients to easily access markets in the Middle East, Africa and South Asia. It caters to the unique requirements of small, medium and large businesses with four free zone parks including business centre facilities, offices, warehouses and land for development, as well as facilities for educational institutions. Since its inception 15 years ago, RAK FTZ has diversified from its traditional focus on industrial manufacturing to also support trading, sales and marketing activities, a wide range of service sectors, as well as logistics and distribution platforms. To learn more about RAK FTZ, please visit

Media Contact:

Cleo Eleazar
Sr. Manager – PR & Events – RAK FTZ
Phone: +971-7-2077173
Source: Ras Al Khaimah Free Trade Zone (RAK FTZ)

Written by asiafreshnews

June 4, 2015 at 5:37 pm

Posted in Uncategorized